A hematopoietic protein tyrosine phosphatase (HePTP) gene that is amplified and overexpressed in myeloid malignancies maps to chromosome 1q32.1.
Tyrosine phosphorylation is an important regulator of cell growth and differentiation reflecting the interaction of protein tyrosine kinases (PTK) and protein tyrosine phosphatases (PTP). Although excessive PTK activity can result in hematopoietic cell transformation, perturbation of either of these two modulators may result in uncontrolled cell growth. Myeloid cells are responsive to growth factors and cytokines that induce tyrosine phosphorylation and can become ligand independent when endogenous PTKs become dysregulated. Specific PTPs, through mutation or altered expression, may enhance PTK activities and also cause myeloid ligand independence, though this has not yet been demonstrated. We have previously reported the isolation of a hematopoietic specific cytoplasmic PTP (HePTP). We now report that this gene maps to chromosome 1q32.1 utilizing fluorescent in situ chromosomal hybridization (FISH). This site is frequently amplified in preleukemic myeloproliferative diseases. FISH analysis of a patient with myelodysplastic syndrome characterized by myeloid hypoplasia and monocytosis reveals triplication of the HePTP gene on one allele with elevated protein expression in neoplastic myelomonocytic cells. Elevated expression is also identified in blasts from some patients with acute leukemia. These observations prompted us to examine the experimental effects on cell growth of HePTP overexpression. Though normal myeloid cells show minimal HePTP expression, all hematopoietic cell lines tested show high expression of HePTP. Gene transfer of HePTP into NIH 3T3 cells was therefore performed, which caused altered cell morphology, disorganized growth, anchorage independent colony formation and subtle differences in the pattern of tyrosine phosphoproteins compared to control cell lines. We conclude that amplification and overexpression of HePTP may be an important cofactor contributing to abnormal myeloid cell growth.
Zanke
B
B
Department of Medicine, University of Toronto, Princess Margaret Hospital, Canada.
Squire
J
J
Griesser
H
H
Henry
M
M
Suzuki
H
H
Patterson
B
B
Minden
M
M
Mak
T W
TW
D000328:Adult; D002874:Chromosome Mapping; D002878:Chromosomes, Human, Pair 1; D005260:Female; D005347:Fibroblasts / Q000201:enzymology / Q000473:pathology; D005784:Gene Amplification; D015870:Gene Expression; D018014:Gene Transfer Techniques; D005796:Genes; D006413:Hematopoietic System / Q000201:enzymology*; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D015470:Leukemia, Myeloid, Acute / Q000201:enzymology / Q000235:genetics*; D008297:Male; D009190:Myelodysplastic Syndromes / Q000201:enzymology / Q000235:genetics; D017027:Protein Tyrosine Phosphatases / Q000235:genetics*
D017027:Protein Tyrosine Phosphatases